Management of Post‑Viral Laryngitis

Natural History and Initial Observation

Viral laryngitis is a self‑limited condition that resolves spontaneously in 1–3 weeks (typically 7–10 days to 3 weeks) without any medical intervention. The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) recommends expectant observation as the initial management for new‑onset dysphonia suspected to be viral. 1
The most common viral etiologies are parainfluenza, rhinovirus, influenza, and adenovirus. 1

Routine antibiotics are not indicated for dysphonia caused by viral laryngitis. The AAO‑HNS advises against prescribing antibiotics in these cases. 2
A Cochrane systematic review found no objective benefit of antibiotics in acute laryngitis. 1
Unnecessary antibiotic use exposes patients to adverse effects (rash, abdominal pain, diarrhea, vomiting), promotes antimicrobial resistance, and increases the risk of laryngeal candidiasis. 1
Antibiotics should be reserved only for immunocompromised patients or when a bacterial infection is confirmed (e.g., laryngeal tuberculosis, pertussis, bacterial laryngotracheitis). 1

Empiric systemic corticosteroids are not recommended for viral laryngitis because of a limited evidence base and a significant risk profile. The AAO‑HNS advises against routine steroid use. 2
Reported steroid‑related risks include avascular necrosis, pancreatitis, new‑onset diabetes, laryngeal candidiasis, and dose‑dependent pharyngitis. 2
Selective use of a short course of steroids may be considered only in highly selected situations (e.g., professional voice users with urgent vocal demands or allergic laryngitis) after shared decision‑making that discusses risks versus modest benefits. 3

Persistent dysphonia beyond 4 weeks warrants laryngoscopic evaluation (consensus recommendation). 4
Laryngoscopy is indicated when serious underlying concerns exist at presentation, such as potential malignancy or a significant impact on a professional voice user’s livelihood. 4
Professional voice users who cannot wait for spontaneous recovery should be referred for early laryngoscopy. 5
Persistent symptoms beyond the expected 1–3 week viral course raise suspicion for alternative pathologies that are less likely to resolve spontaneously. 6
Direct visualization of the larynx is the principal method to refine the differential diagnosis and guide targeted therapy. 6
Early laryngoscopy helps prevent delays in diagnosing malignancy or other serious conditions. 5

Do not reflexively prescribe antibiotics for hoarseness when a bacterial cause is not evident; most cases are viral. 1
Do not use steroids empirically without a documented indication and shared decision‑making. 2
Do not delay laryngoscopy beyond 4 weeks in patients with persistent dysphonia, to avoid postponing diagnosis of serious disease. 4
Do not prescribe anti‑reflux medication empirically for hoarseness unless the patient has GERD symptoms or laryngoscopic evidence of chronic laryngitis. 7

In patients presenting with hoarseness without gastro‑oesophageal reflux symptoms (e.g., heartburn, regurgitation) or laryngoscopic signs of chronic laryngitis, initiating empiric proton‑pump inhibitor (PPI) therapy does not improve voice outcomes; the evidence shows no benefit for this indication. 8
A systematic review of 9 placebo‑controlled randomized trials evaluating PPIs for suspected reflux‑related dysphonia found that only 3 trials demonstrated a therapeutic benefit, while the remaining 6 showed no difference compared with placebo, indicating limited and inconsistent efficacy. Strength of evidence: moderate (multiple RCTs with mixed results). 8
Prolonged use of PPIs is associated with a range of adverse effects, including cognitive impairment, bacterial gastroenteritis, community‑acquired pneumonia, hip fractures, vitamin B12 deficiency, hypomagnesemia, and chronic kidney disease; these risks must be weighed against the minimal or absent benefit for isolated dysphonia. Strength of evidence: moderate (observational data and pharmacovigilance reports). 8